{"disease":{"id":"transplant-rejection","name":"transplant rejection"},"drugs":{"marketed":[{"drug_id":"cyclosporine","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"cyclosporine","company_name":"Novartis AG (originally Sandoz)","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"Calcineurin inhibitor (immunosuppressant)","quality_score":67,"revenue":"1866.0","mechanism":"Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection."},{"drug_id":"cyclosporine","indication_name":"Prevention of Liver Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"cyclosporine","company_name":"Novartis AG (originally Sandoz)","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"Calcineurin inhibitor (immunosuppressant)","quality_score":67,"revenue":"1866.0","mechanism":"Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection."},{"drug_id":"cyclosporine","indication_name":"Prevention of Cardiac Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"cyclosporine","company_name":"Novartis AG (originally Sandoz)","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"Calcineurin inhibitor (immunosuppressant)","quality_score":67,"revenue":"1866.0","mechanism":"Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection."},{"drug_id":"ciclosporin","indication_name":"Prevention of Cardiac Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"Ciclosporin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform","drug_class":"Calcineurin Inhibitor Immunosuppressant [EPC]","quality_score":68,"revenue":"1866.0","mechanism":""},{"drug_id":"ciclosporin","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"Ciclosporin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform","drug_class":"Calcineurin Inhibitor Immunosuppressant [EPC]","quality_score":68,"revenue":"1866.0","mechanism":""},{"drug_id":"ciclosporin","indication_name":"Prevention of Liver Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"Ciclosporin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform","drug_class":"Calcineurin Inhibitor Immunosuppressant [EPC]","quality_score":68,"revenue":"1866.0","mechanism":""},{"drug_id":"tacrolimus","indication_name":"Liver transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"tacrolimus","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"tacrolimus","indication_name":"Prevention of Liver Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"tacrolimus","indication_name":"Prevention of Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"tacrolimus","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"tacrolimus","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"tacrolimus","indication_name":"Prevention of Cardiac Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"everolimus","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"ciclosporine","indication_name":"Prevention of Cardiac Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ciclosporine","company_name":"Hospices Civils de Lyon","drug_phase":"phase_3","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"ciclosporine","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ciclosporine","company_name":"Hospices Civils de Lyon","drug_phase":"phase_3","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"ciclosporine","indication_name":"Prevention of Liver Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ciclosporine","company_name":"Hospices Civils de Lyon","drug_phase":"phase_3","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"muromonab","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Muromonab","company_name":"St. Jude Children's Research Hospital","drug_phase":"phase_2","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Prevention of Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"belatacept","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nulojix","generic_name":"BELATACEPT","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"T-lymphocyte activation antigen CD80","drug_class":"Selective T Cell Costimulation Blocker [EPC]","quality_score":52,"revenue":null,"mechanism":"Nulojix blocks the activation of T cells by binding to CD80, preventing an immune response."},{"drug_id":"triamcinolone","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Prevention of Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mycophenolate-mofetil","indication_name":"Prevention of Cardiac Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cellcept","generic_name":"MYCOPHENOLATE MOFETIL","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":10,"revenue":null,"mechanism":"Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides."},{"drug_id":"mycophenolate-mofetil","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cellcept","generic_name":"MYCOPHENOLATE MOFETIL","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":10,"revenue":null,"mechanism":"Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides."},{"drug_id":"mycophenolate-mofetil","indication_name":"Prevention of Liver Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cellcept","generic_name":"MYCOPHENOLATE MOFETIL","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":10,"revenue":null,"mechanism":"Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides."},{"drug_id":"mycophenolic-acid","indication_name":"Prevention of Cardiac Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycophenolate","generic_name":"MYCOPHENOLIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mycophenolic-acid","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycophenolate","generic_name":"MYCOPHENOLIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mycophenolic-acid","indication_name":"Prevention of Liver Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycophenolate","generic_name":"MYCOPHENOLIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"muromonab-cd3","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orthoclone Okt3","generic_name":"MUROMONAB-CD3","company_name":"Ortho Biotech","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"CD3 Blocker Immunosuppressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sirolimus","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rapamune","generic_name":"sirolimus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"mTOR Inhibitor Immunosuppressant [EPC]","quality_score":80,"revenue":null,"mechanism":"Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells."},{"drug_id":"daclizumab","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zenapax","generic_name":"DACLIZUMAB","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Interleukin-2 Receptor Blocking Antibody","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"neoral","indication_name":"Prevention of Cardiac Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neoral","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"neoral","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neoral","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"neoral","indication_name":"Prevention of Liver Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neoral","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cyclosporin","indication_name":"Prevention of Cardiac Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclosporin","company_name":"Karolinska University Hospital","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cyclosporin","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclosporin","company_name":"Karolinska University Hospital","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cyclosporin","indication_name":"Prevention of Liver Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclosporin","company_name":"Karolinska University Hospital","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nulojix","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nulojix","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"rapamycin","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamycin","company_name":"Institut National de la Santé Et de la Recherche Médicale, France","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"simulect","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Simulect","company_name":"Astellas Pharma Inc","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor subunit alpha","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"zenapax","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zenapax","company_name":"National Institute of Neurological Disorders and Stroke (NINDS)","drug_phase":"phase_3","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"basiliximab","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chrft5","generic_name":"BASILIXIMAB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor subunit alpha","drug_class":"Interleukin-2 Receptor Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"rapamune","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rapamune","company_name":"Wyeth is now a wholly owned subsidiary of Pfizer","drug_phase":"marketed","molecular_target":"Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"hydrocortisone-succinate","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"azathioprine","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Transplanted organ rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"mycophenolate","indication_name":"Prevention of Cardiac Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mycophenolate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 1, Inosine-5'-monophosphate dehydrogenase 2, Inosine-5'-monophosphate dehydrogenase (IMPDH)","drug_class":"","quality_score":42,"revenue":null,"mechanism":null},{"drug_id":"mycophenolate","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mycophenolate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 1, Inosine-5'-monophosphate dehydrogenase 2, Inosine-5'-monophosphate dehydrogenase (IMPDH)","drug_class":"","quality_score":42,"revenue":null,"mechanism":null},{"drug_id":"mycophenolate","indication_name":"Prevention of Liver Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mycophenolate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 1, Inosine-5'-monophosphate dehydrogenase 2, Inosine-5'-monophosphate dehydrogenase (IMPDH)","drug_class":"","quality_score":42,"revenue":null,"mechanism":null},{"drug_id":"afinitor","indication_name":"Prevention of Kidney Transplant Rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"imlifidase","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ides","generic_name":"IMLIFIDASE","company_name":"Hansa Biopharma AB","drug_phase":"marketed","molecular_target":"Immunoglobulin gamma (IgG), heavy chain","drug_class":"","quality_score":20,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":63,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06348446","title":"Tacrolimus Exposure in Kidney Transplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":12000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06496269","title":"Impact of Microvascular Inflammation on Kidney Allograft Outcome","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Paris Translational Research Center for Organ Transplantation","has_results":false},{"nct_id":"NCT04091984","title":"The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Natera, Inc.","has_results":false},{"nct_id":"NCT06394596","title":"Predicting Prognostic Factors in Kidney Transplantation Using A Machine Learning","phase":"","overall_status":"COMPLETED","enrollment_count":4077,"lead_sponsor_name":"Sung Shin","has_results":false},{"nct_id":"NCT05306795","title":"Development and Validation of a Comprehensive Classification Automation System for Kidney Allograft Biopsies","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Paris Translational Research Center for Organ Transplantation","has_results":false},{"nct_id":"NCT03326076","title":"Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"CareDx","has_results":false},{"nct_id":"NCT04787822","title":"Long Term Follow up of the LTOG Cohort","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06399302","title":"Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":2600,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05934617","title":"Trajectories of FEV1 After Lung Transplantation","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2500,"lead_sponsor_name":"Paris Translational Research Center for Organ Transplantation","has_results":false},{"nct_id":"NCT06505200","title":"Observational Cohort Study Renal Transplantation University Hospitals Leuven","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1891,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT03466775","title":"Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":1845,"lead_sponsor_name":"Paris Translational Research Center for Organ Transplantation","has_results":false},{"nct_id":"NCT02525510","title":"Deceased Organ Donor Interventions to Protect Kidney Graft Function","phase":"NA","overall_status":"COMPLETED","enrollment_count":1427,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06016283","title":"Sex Impact on Long-term Outcomes of LDKT","phase":"","overall_status":"COMPLETED","enrollment_count":1276,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT06365411","title":"GEnomic Medicine in Kidney Transplantation Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Western Sydney Local Health District","has_results":false},{"nct_id":"NCT04566055","title":"Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"CareDx","has_results":false},{"nct_id":"NCT05715853","title":"Prospective Assessment of Rejection in Kidney Transplant (PARK)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"NephroSant","has_results":false},{"nct_id":"NCT03487861","title":"Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT06087003","title":"Pediatric Induction Therapy in Kidney Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":958,"lead_sponsor_name":"Gang Chen","has_results":false},{"nct_id":"NCT03255265","title":"Clinical Study of Microchimerism and cfDNA as Biomarkers for Acute Rejection After Organ Transplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":950,"lead_sponsor_name":"Fuzhou General Hospital","has_results":false},{"nct_id":"NCT03582436","title":"Rejection Diagnosis in Kidney Transplants Patients","phase":"","overall_status":"COMPLETED","enrollment_count":824,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04792294","title":"Multicenter Analysis of Efficacy and Outcomes of Extracorporeal Photopheresis as Treatment of Chronic Lung Allograft Dysfunction","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT06453148","title":"Brazilian Clinical Registry of Heart Transplantation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":730,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT04694573","title":"Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Heidelberg University","has_results":false},{"nct_id":"NCT07231328","title":"PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Transplant Genomics, Inc.","has_results":false},{"nct_id":"NCT03393793","title":"HEart trAnsplantation Registry of piTie-Salpetriere University Hospital","phase":"","overall_status":"COMPLETED","enrollment_count":566,"lead_sponsor_name":"Lee S Nguyen","has_results":false},{"nct_id":"NCT03652402","title":"Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN","phase":"","overall_status":"COMPLETED","enrollment_count":558,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05050955","title":"AlloSure Lung Assessment and Metagenomics Outcomes Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":550,"lead_sponsor_name":"CareDx","has_results":false},{"nct_id":"NCT04727788","title":"Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":550,"lead_sponsor_name":"Verici Dx","has_results":false},{"nct_id":"NCT02109575","title":"Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)","phase":"","overall_status":"COMPLETED","enrollment_count":540,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT07412470","title":"A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":526,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04126746","title":"Clinical Trials in Organ Transplantation Extension Study","phase":"","overall_status":"COMPLETED","enrollment_count":501,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT07145944","title":"To Explore the Application Value of Magnetic Resonance Imaging in Noninvasive Quantitative Evaluation of Graft Function and Systemic Metabolism After Renal Transplantation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04341103","title":"AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"CareDx","has_results":false},{"nct_id":"NCT06314230","title":"Australian Genomics Of Chronic Allograft Dysfunction Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Western Sydney Local Health District","has_results":false},{"nct_id":"NCT05707520","title":"Long-term Benefit of MPA in Liver Transplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05655208","title":"Histological Profiles of Lung Allograft Transbronchial Biopsies and Clinical Outcomes After Lung Transplantation","phase":"","overall_status":"COMPLETED","enrollment_count":498,"lead_sponsor_name":"Paris Translational Research Center for Organ Transplantation","has_results":false},{"nct_id":"NCT06436027","title":"Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.","phase":"","overall_status":"COMPLETED","enrollment_count":496,"lead_sponsor_name":"Paris Translational Research Center for Organ Transplantation","has_results":false},{"nct_id":"NCT02727296","title":"Volatile Anesthetic Protection Of Renal Transplants 2","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":488,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT03719339","title":"VIRTUUS Children's Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":445,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT05816486","title":"BIOtechnology Applied to Renal TRansplantation With IMmunobiogram","phase":"","overall_status":"COMPLETED","enrollment_count":443,"lead_sponsor_name":"Biohope Scientific Solutions for Human Health, S.L.","has_results":false},{"nct_id":"NCT05747274","title":"SRDK0921_ Analytical Performance Study","phase":"","overall_status":"COMPLETED","enrollment_count":439,"lead_sponsor_name":"BioMAdvanced Diagnostics","has_results":false},{"nct_id":"NCT03206801","title":"Urine CXCL10 Monitoring Trial in Kidney Transplant","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":420,"lead_sponsor_name":"University of Manitoba","has_results":false},{"nct_id":"NCT05205551","title":"Prospera Test Evaluation in Cardiac Transplant (ProTECT)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":411,"lead_sponsor_name":"Natera, Inc.","has_results":false},{"nct_id":"NCT00339209","title":"Prospective Lung Transplant Database for Genetic Research","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT05897047","title":"The smartNTx Trial: A Prospective, Randomized Controlled Trial (RCT) to Investigate Additional Interventional Telemedical Management Versus Standard Aftercare in Kidney Transplant Recipients (KTR)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":384,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT03102125","title":"Allograft Dysfunction in Heart Transplant","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":376,"lead_sponsor_name":"Paul Kim","has_results":false},{"nct_id":"NCT06216015","title":"Exercise Training and Kidney Transplantation","phase":"NA","overall_status":"COMPLETED","enrollment_count":345,"lead_sponsor_name":"Hugo de Luca Correa","has_results":false},{"nct_id":"NCT06740578","title":"Evaluation of the Added Clinical Value of Donor-derived Cell-free DNA for the Monitoring of Cardiac Allograft Rejection.","phase":"","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"Paris Translational Research Center for Organ Transplantation","has_results":false},{"nct_id":"NCT06351488","title":"Detection of Circulating Kidney DNA in Kidney Transplant Patients Facing an Episode of Graft Rejection","phase":"","overall_status":"RECRUITING","enrollment_count":319,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03874299","title":"The TOGETHER Project - Kidney RNA-seq Validation","phase":"","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}